Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment.
Chi XuYahui WangYuanyuan HongRu YaoLijia WuXi ShenYang QuZhuo ZhangWei ZhuYing YangWeizhi ChenYidong ZhouZhiyong LiangPublished in: Breast cancer research and treatment (2023)
Aberrant activation of multiple pathways and low baseline tumor-infiltrating B cells are related to HER2 + BC trastuzumab-based recurrence, which primarily affects the antitumor activity of trastuzumab.